The CDPath prognostic tool gives Crohn's patients risk scores for serious complications within three years, so they can make more informed treatment decisions.
The Seattle-based company recently published immune repertoire data showing the potential of T-cell receptor profiling in IBD diagnostics.
Coral Genomics, Crohn's & Colitis Foundation Partner on Study of IBD Treatment Response
San Francisco-based Coral will study up to 1,000 patients in an IBD cohort as it develops a test to predict patient response to treatment.
The company has slightly extended its timeline for launching a Lyme disease test to focus on marketing its COVID assay for immunocompromised individuals.
The firm is expanding its plans from a Crohn's disease test to a broader GI differential diagnostic and continues to expect to launch its Lyme disease assay by year-end.